- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產品
- 聯(lián)系我們
Tubacin 是一種高度有效的選擇性的,可逆的,細胞滲透性HDAC6抑制劑,無細胞試驗中IC50為4 nM,比作用于HDAC1的選擇性高350倍。Tubacin 可通過減少病毒RNA合成來抑制乙型腦炎病毒的復制。
Tubacin Chemical Structure
CAS: 537049-40-4
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
HeLa | Function assay | 6 hrs | Inhibition of HDAC6 in human HeLa cells assessed as reduction in K40 hyperacetylation of alpha-tubulin incubated for 6 hrs by immunofluorescence assay, IC50=2.9μM | 25454270 | |
A549 | Function assay | 20 hrs | Inhibition of HDAC-6 in human A549 cells assessed as induction of alpha-tubulin acetylation after 20 hrs by cytoblot analysis, EC50=2.5μM | ChEMBL | |
RAW264.7 | Function assay | Protection against Bacillus anthracis protective antigen and lethal toxin-diphtheria toxin chimeric protein mediated cytotoxicity in mouse RAW264.7 cells assessed as cell viability | 16408003 | ||
T24 | Function assay | Induction of histone H3 acetylation in human T24 cells, EC50=2.9μM | 19111466 | ||
mammalian cells | Function assay | Tested for inhibition of Histone deacetylase 6 induced acetylated tubulin in mammalian cells, EC50=2.9μM | 14584932 | ||
CHO | Function assay | Inhibition of Bacillus anthracis anthrax protective antigen heptamer pre-pore to pore conversion in CMG2-expressing CHO cells | 23964961 | ||
DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | ||
SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | ||
SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | ||
LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | ||
BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | ||
Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | ||
OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | ||
MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | ||
Rh30 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 29435139 | ||
Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | ||
點擊查看更多細胞系數據 |
產品描述 | Tubacin 是一種高度有效的選擇性的,可逆的,細胞滲透性HDAC6抑制劑,無細胞試驗中IC50為4 nM,比作用于HDAC1的選擇性高350倍。Tubacin 可通過減少病毒RNA合成來抑制乙型腦炎病毒的復制。 | ||
---|---|---|---|
特性 | 第一個已知的選擇性α-微管蛋白脫乙酰基抑制劑。 | ||
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | 在A549細胞中,Tubacin增加α微管蛋白乙?;恢苯臃€(wěn)定微管,EC50 是2.5 μM。Tubacin抑制HDAC6介導的α-微管蛋白去乙?;?,并抑制野生型和HDAC6過表細胞的遷移。[2]Tubacin聯(lián)合使用顯著增加微管蛋白乙?;?。[3]Tubacin顯著抑制藥物敏感和耐藥的MM細胞的生長,IC50 是 5–20 μM,并且通過激活caspases誘導細胞凋亡。[4] |
|||
---|---|---|---|---|
激酶實驗 | 酶抑制試驗 | |||
酶抑制實驗通過Reaction Biology HDAC Spectrum平臺進行。HDAC1, 2, 4, 5, 6, 7, 8, 9, 10, 和 11的測試用離體重組的人類蛋白,HDAC3/NcoR2 復合體用于HDAC3實驗。HDAC1, 2, 3, 6, 10, 和11的底物是來自P53殘基379-382 (RHKKAc)的熒光肽;HDAC8的底物是基于p53 (RHKAcKAc)殘基379-382的熒光二肽。Acetyl-Lys(三氟乙酰)-AMC作為實驗HDAC4, 5, 7,和 9的底物?;衔锶苡贒MSO,以30 μM為初始濃度,3倍連續(xù)稀釋,測定10個劑量的IC50。對照化合物Trichostatin A (TSA)初始濃度為5uM,3倍連續(xù)稀釋,測定10個劑量的IC50。IC50值通過計算劑量反應曲線的斜率得到。 | ||||
細胞實驗 | 細胞系 | 藥物敏感性(MM.1S, U266, INA-6, 和RPMI8226) 和耐藥性(RPMI-LR5 和 RPMI-Dox40) MM 細胞系 | ||
濃度 | ~20 μM | |||
孵育時間 | 72小時 | |||
方法 | 對MM細胞生長的抑制作用通過溴化噻唑藍四氮唑(MTT)染料吸收值測定。所有實驗重復4次。 |
|||
實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
Western blot | Acetyl-α-tubulin / α-tubulin / pERK / ERK / p-MLC / MLC | 26783207 | ||
Immunofluorescence | p62 / HDAC6 Phalloidin / MYH9 Acetylated Microtubules / Viral HA | 26643866 | ||
Growth inhibition assay | Cell viability | 29845122 |
體內研究(In Vivo) | ||
體內研究活性 | 在雞胚中,Tubacin抑制HDAC6活性而降低人工基底膜/聚酰胺纖維篩孔中新生血管的形成。在angioreactors移植的小鼠模型中,Tubacin也會損壞新血管形成。[5] |
|
---|---|---|
動物實驗 | Animal Models | 植入angioreactors的無胸腺裸鼠 |
Dosages | -- | |
Administration | Tubacin填滿半閉合的angioreactors, 隨后植入小鼠體內。 |
分子量 | 721.86 | 分子式 | C41H43N3O7S |
CAS號 | 537049-40-4 | SDF | -- |
Smiles | C1C(OC(OC1C2=CC=C(C=C2)CO)C3=CC=C(C=C3)NC(=O)CCCCCCC(=O)NO)CSC4=NC(=C(O4)C5=CC=CC=C5)C6=CC=CC=C6 | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
DMSO : 100 mg/mL ( (138.53 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
體內溶解度 現配現用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內配方計算器 |
動物體內配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項